A new 'tac' for childhood nephrotic syndrome.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 23128115.
- Also identified by DOI 10.1038/ki.2012.272.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Calcineurin inhibitors (CNIs) are frequent first-line agents in children with steroid-resistant nephrotic syndrome (SRNS). However, limited randomized controlled trial (RCT) data are available comparing CNIs with alternative therapies. Gulati and colleagues report their experience with tacrolimus versus cyclophosphamide in childhood SRNS. Their results establish clear superiority of tacrolimus over cyclophosphamide and give further proof that RCTs in childhood SRNS are both feasible and vital for improving the standard of care.
Medical subject headings
- Cyclophosphamide
- Immunosuppressive Agents
- Nephrotic Syndrome
- Prednisolone
- Tacrolimus